MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

Rhea-AI Summary

MyMD Pharmaceuticals (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,096,933, securing methods for administering MYMD-1 to treat chronic inflammation-related disorders, particularly fibrosis and asthma. This patent marks the thirteenth supporting MYMD-1's development as a treatment for autoimmune and age-related diseases. The compound has shown potential in regulating the immune system and addressing diseases like idiopathic pulmonary fibrosis, which affects nearly 100,000 individuals in the U.S.

Positive

• Issuance of U.S. Patent No. 11,096,933 strengthens MYMD-1's market position.
• MYMD-1 demonstrates potential anti-inflammatory and anti-fibrotic properties.
• Thirteenth patent adds to the intellectual property portfolio of MYMD.

Negative

• None.

Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma

BALTIMORE--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders Associated with Chronic Inflammation.”

The ’933 patent becomes the thirteenth patent protecting the Company’s lead candidate MYMD-1, a synthetic small molecule being developed to treat autoimmune and age-related diseases, including extending human lifespan, and which has been shown effective in regulating the immune system in preclinical studies.

"Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer. “This latest patent underscores MYMD-1’s potential to inhibit inflammation, which is linked to myriad diseases including IPF.”

A study conducted by Eurofins Discovery Phenotypic Center of Excellence identified the potential of MYMD-1 to limit the fibrotic biology associated with IPF. Hallmark activities of MYMD-1 included inhibition of transforming growth factor-beta (TGF-beta), a driver for fibrosis, and of tumor necrosis factor (TNF), associated with inflammation. This dual pattern of anti-fibrotic and anti-inflammatory activities are consistent with the potential for MYMD-1 to be developed as a therapeutic candidate for fibrosis-related diseases.

Fibrotic disorders are implicated in nearly 45% of all deaths in the developed world, and may involve multiple physiological systems including the skin, liver, kidney, heart and lungs. In particular, IPF has an insidious, relentless and chronic course, with a median survival of two to five years. Thus, there is a great need to develop new and effective therapeutics for treating patients.

About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease and decline rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α, a driver of chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Based on a novel synthetic derivative of cannabidiol (CBD), Supera-CBD is being developed to address the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005213/en/

Investor Contact:

Robert Schatz

(646) 421-9523

rschatz@mymd.com

www.mymd.com

Source: MyMD Pharmaceuticals, Inc.

FAQ

What does the recent patent for MYMD-1 cover?

The recent patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, focusing on fibrosis and asthma.

How many patents does MyMD Pharmaceuticals have for MYMD-1?

MyMD Pharmaceuticals has secured thirteen patents protecting MYMD-1.

What is the significance of MYMD-1 for idiopathic pulmonary fibrosis?

MYMD-1 shows potential to inhibit inflammation linked to idiopathic pulmonary fibrosis, which has no effective treatment options currently.

How many people in the U.S. are affected by idiopathic pulmonary fibrosis?

Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis.

What role does MYMD-1 play in treating autoimmune diseases?

MYMD-1 is being developed to treat autoimmune and age-related diseases by regulating the immune system.